KR900700613A - 인간의 파라인플루엔자 바이러스 타입 3의 면역원성 단편을 함유하는 키메라 당단백질 - Google Patents

인간의 파라인플루엔자 바이러스 타입 3의 면역원성 단편을 함유하는 키메라 당단백질

Info

Publication number
KR900700613A
KR900700613A KR1019890702416A KR890702416A KR900700613A KR 900700613 A KR900700613 A KR 900700613A KR 1019890702416 A KR1019890702416 A KR 1019890702416A KR 890702416 A KR890702416 A KR 890702416A KR 900700613 A KR900700613 A KR 900700613A
Authority
KR
South Korea
Prior art keywords
glycoprotein
polypeptide
immunogenic fragment
expression system
human
Prior art date
Application number
KR1019890702416A
Other languages
English (en)
Other versions
KR970009347B1 (en
Inventor
워덴 마이클
Original Assignee
로버트 에이. 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이. 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이. 아미테이지
Publication of KR900700613A publication Critical patent/KR900700613A/ko
Application granted granted Critical
Publication of KR970009347B1 publication Critical patent/KR970009347B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

내용 없음

Description

인간의 파라인플루엔자 바이러스 타입 3의 면역원성 단편을 함유하는 키메라 당단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 신호 서열 및 인간의 파라인플루엔자 바이러스 타입 3당단백질 F 및 HN으로부터의 적어도 하나의 면역원성 단편을 포함하는 폴리펩타이드.
  2. 제1항에 있어서, 상기 폴리펩타이드가, N말단으로 시작하여, 당단백질 F로부터의 신호 서열, 당단백질F의 면역원성 단편 및 당단백질 HN의 면역원성 단편인 폴리펩타이드.
  3. 제1항의 폴리펩타이드를 포함하는 인간용 백신.
  4. 제3항에 있어서, 상기 폴리펩타이드가, N말단으로 시작하여, 당단백질 F로부터의 신호 서열, 당단백질 F의 면역원성 단편 및 당단백질 HN의 면역원성 단편인 백신.
  5. 예방접종에 의해 인간의 파라인플루엔자 바이러스 타입3으로부터 인간을 보호하는 백신을 제조하기 위한 제1항의 폴리펩타이드의 용도.
  6. 제5항에 있어서, 상기 폴리펩타이드가, N말단으로 시작하여, 당단백질 F로부터의 신호 서열, 당단백질 F의 면역원성 단편 및 당단백질 HN의 면역원성 단편인 용도.
  7. 제1항의 폴리펩타이드를 발현시킬 수 있는 DNA 서열을 함유한 적절한 숙주를 포함하는 발현시스템.
  8. 제7항에 있어서, 상기 DNA 서열이 N말단으로 시작하여, 당단백질 F로부터의 신호 서열, 당단백질 F의 면역원성 단편 및 당단백질 HN의 면역원성 단편인 폴리펩타이드를 제조하는 발현시스템.
  9. 제7항에 있어서, 상기 적절한 숙주가 박테리아 세포, 효모세포, 포유동물 세포 및 곤충세포로 구성되는 그룹으로부터의 선택된 발현시스템.
  10. 제9항에 있어서, 상기 적절한 숙주가 이. 콜라이 박테리아, 차이니즈 햄스터 난소 세포, 뮤린(murine, 쥐과의 일종) C127 세포 및 에스. 프러지페르다(S. Frugiperda) 세포로 구성되는 그룹으로부터 선택된 발현시스템.
  11. 제7항에 있어서, 상기 적절한 숙주가 상기 폴리펩타이드를 분비하는 발현시스템.
  12. 제7항에 있어서, 상기 DNA 서열이 플라스미드안에 함유된 발현시스템.
  13. 제12항에 있어서, 상기 플라스미드가 시토메갈로바이러스(Cytomegalovirus) 프로모터의 조절하에 있는 발현시스템.
  14. 제12항에 있어서, 적절한 진핵 세포중에서 상기 플라스미드의 복제가 소 유두종 바이러스 DNA 서열의 조절하에 있는 발현시스템.
  15. 제7항에 있어서, 상기 DNA 서열이 바큘로바이러스과의 재조합 바이러스안에 함유된 발현시스템.
  16. 제15항에 있어서, 상기 바이러스가 오토그라파 캘리포니카 뉴클리어 폴리헤드로시스 바이러스(Autogra pha Californica nuclear polyhedrosis virus)의 발현시스템.
  17. 인간의 파라인플루엔자 바이러스 타입 3당단백질 F 및 HN으로부터의 적어도 하나의 면역원성 단편을 포함하는 폴리펩티드.
  18. 제17항의 폴리펩타이드를 포함하는 인간용 백신.
  19. 예방접종에 의해 인간의 파라인플루엔자 바이러스 타입3으로부터 인간을 보호하는 백신을 제조하기 위한 제17항의 폴리펩타이드의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR89702416A 1988-04-22 1989-12-21 Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3 KR970009347B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18464888A 1988-04-22 1988-04-22
US07/184,648 1988-04-22
PCT/US1989/000814 WO1989010405A1 (en) 1988-04-22 1989-03-03 Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3

Publications (2)

Publication Number Publication Date
KR900700613A true KR900700613A (ko) 1990-08-16
KR970009347B1 KR970009347B1 (en) 1997-06-10

Family

ID=22677770

Family Applications (1)

Application Number Title Priority Date Filing Date
KR89702416A KR970009347B1 (en) 1988-04-22 1989-12-21 Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3

Country Status (12)

Country Link
US (2) US5169628A (ko)
EP (1) EP0413695B1 (ko)
KR (1) KR970009347B1 (ko)
AT (1) ATE105334T1 (ko)
AU (1) AU611784B2 (ko)
CA (1) CA1306709C (ko)
DE (1) DE68915165T2 (ko)
DK (1) DK172635B1 (ko)
FI (1) FI102616B (ko)
HK (1) HK37397A (ko)
NO (1) NO303499B1 (ko)
WO (1) WO1989010405A1 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
JP2649285B2 (ja) * 1990-11-29 1997-09-03 藤倉化成株式会社 ヒトパラインフルエンザ４ａ型ウイルスフュージョンプロテイン遺伝子及び該遺伝子を含む物質
GB9120221D0 (en) * 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5550017A (en) * 1993-10-12 1996-08-27 Emory University Anti-paramyxovirus screening method and vaccine
US7300918B2 (en) 1994-01-14 2007-11-27 Matthias Rath Method of producing vaccines from protein signal oligopeptides
EP0744027B1 (en) * 1994-01-14 2005-03-16 Rath, Matthias, Dr. med. Use of methods for identifying hydrophilic signal oligopeptides
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
AU724621B2 (en) * 1996-01-29 2000-09-28 Georgetown University Amplification of response from expressed recombinant protein
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
JP2002512003A (ja) 1997-11-14 2002-04-23 コノート ラボラトリーズ リミテッド パラミキソウイルスワクチンのためのアルファウイルスベクター
BR0010322A (pt) 1999-05-06 2002-04-09 Univ Wake Forest Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
CN101921732A (zh) 2001-01-19 2010-12-22 维洛诺瓦蒂夫公司 在易感哺乳动物中引起呼吸道疾病的病毒
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
IL163646A0 (en) 2002-02-21 2005-12-18 Vironovative Bv Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
BRPI0411099A (pt) * 2003-06-05 2006-07-18 Wyeth Corp composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2021119293A2 (en) * 2019-12-10 2021-06-17 Children's National Medical Center T-cell epitopes of human parainfluenza virus 3 for adoptive t-cell immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
NZ230425A (en) * 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector

Also Published As

Publication number Publication date
DK251890A (da) 1990-10-18
NO904538L (no) 1990-12-27
JPH03503760A (ja) 1991-08-22
FI102616B1 (fi) 1999-01-15
CA1306709C (en) 1992-08-25
KR970009347B1 (en) 1997-06-10
NO904538D0 (no) 1990-10-19
FI905184A0 (fi) 1990-10-19
WO1989010405A1 (en) 1989-11-02
DE68915165D1 (de) 1994-06-09
US5284764A (en) 1994-02-08
US5169628A (en) 1992-12-08
FI102616B (fi) 1999-01-15
HK37397A (en) 1997-04-04
DK251890D0 (da) 1990-10-18
NO303499B1 (no) 1998-07-20
AU3197589A (en) 1989-11-24
EP0413695B1 (en) 1994-05-04
DK172635B1 (da) 1999-03-22
EP0413695A1 (en) 1991-02-27
ATE105334T1 (de) 1994-05-15
AU611784B2 (en) 1991-06-20
DE68915165T2 (de) 1994-09-08

Similar Documents

Publication Publication Date Title
KR900700613A (ko) 인간의 파라인플루엔자 바이러스 타입 3의 면역원성 단편을 함유하는 키메라 당단백질
ATE131874T1 (de) Eine prokaryotische leader-sequenz enthaltendes bakuloviren-exprimierungssystem
Murphy et al. Enhanced expression, secretion, and large-scale purification of recombinant HIV-1 gp120 in insect cells using the baculovirus egt and p67 signal peptides
BR9813692A (pt) Processos para aumentar o rendimento de umaproteìna recombinante produzida em cultura decélula de inseto e de pestivìrus recombinante e2ou fragmentos ou proteìna erns do mesmo e paraproduzir hormÈnio estimulante folìculorecombinante, alfa-unidades e/ou beta-unidades, ecomplexos e fragmentos dos mesmos uso de umprocesso, e, vacina.
CA2113712A1 (en) Papilloma virus vaccine
NO304381B1 (no) FremgangsmÕte for fremstilling av hepatitt C-virus (HCV) og anvendelse derav i en immunoanalysemetode
DE69535495D1 (de) Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine
KR850003163A (ko) 완전변이 표현 콘트롤 시스템
DE69331194D1 (de) Adeno assozierter virus mit umgekehrten terminal repeat sequenzen als promotor fur den in vivo transfer eines funktionellen cftr gens
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
KR920703831A (ko) 백신(vaccines)
KR927003812A (ko) 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조
KR870005092A (ko) 펲타이드의 제조방법
KR900014428A (ko) 신규폴리펩타이드 및 그 제조방법
Love et al. Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus
KR880002894A (ko) 주혈흡충증왁진으로 사용되는 단백질과 dna 시퀀스
Maruniak et al. Autographa californica nuclear polyhedrosis virus structural proteins compared from in vivo and in vitro sources
EP0251467A3 (en) Compositions and methods of use for a major outer capsid protein (vp7) of rotavirus sa-11
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
KR890701745A (ko) O-결합 글리코실화가 감소된 바이러스 단백질
DE69131984T2 (de) Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
Kato et al. Expression and purification of biologically active porcine follicle-stimulating hormone in insect cells bearing a baculovirus vector
WO1993015197A3 (en) Expression of osteogenic factor op-1 in cells of spodoptera frugiperda infected with recombinant baculovirus
WO2021004561A1 (de) Rubella virus spike konstrukt
Kimura et al. Baculovirus expression, purification, and properties of varicella-zoster virus gE, gI, and the complex they form

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111028

Year of fee payment: 15

EXPY Expiration of term